Antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage increases the risk for deep venous thrombosis: A case-control study

Aneurysmal subarachnoid hemorrhage (aSAH) is a unique form of hemorrhagic stroke caused by rupture of an intracranial aneurysm with an estimated incidence of 10 per 100,000 person-years. [1] Aneurysm re-rupture prior to treatment represents a major source of early morbidity and carries a mortality rate of up to 51%. [2] Efforts to reduce the likelihood of early re-rupture have focused on early intervention for treatment of the aneurysm and administration of antifibrinolytics. Early intervention, either through surgical clipping or endovascular embolization, has proven effective in reducing rates of re-rupture and represents a Class I recommendation in the AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage.

Source: Clinical Neurology and Neurosurgery - September 10, 2015 Category: Neurosurgery Authors: Paul M. Foreman, Michelle Chua, Mark R. Harrigan, Winfield S. Fisher, R. Shane Tubbs, Mohammadali M. Shoja, Christoph J. Griessenauer Source Type: research